Blog
About

3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Autophagic adaptations in diabetic cardiomyopathy differ between type 1 and type 2 diabetes.

      1 , , , , , , , , , , ,

      Autophagy

      AMP-activated protein kinase, AMPK, AMP-activated protein kinase, CTSD, cathepsin D, DM, diabetes mellitus, GFP, green fluorescent protein, HBA1c, glycated hemoglobin α 1, LV, left ventricular, MAP1LC3/LC3, microtubule-associated protein 1 light chain 3, MTOR, mechanistic target of rapamycin, Mn-SOD, superoxide dismutase 2, mitochondrial, SIRT1, sirtuin 1, SQSTM1/p62, sequestosome 1, STZ, streptozotocin, autophagy, cardiomyopathy, chloroquine, diabetes mellitus, insulin, resveratrol, type 1 diabetes, type 2 diabetes, ultrastructure

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Little is known about the association between autophagy and diabetic cardiomyopathy. Also unknown are possible distinguishing features of cardiac autophagy in type 1 and type 2 diabetes. In hearts from streptozotocin-induced type 1 diabetic mice, diastolic function was impaired, though autophagic activity was significantly increased, as evidenced by increases in microtubule-associated protein 1 light chain 3/LC3 and LC3-II/-I ratios, SQSTM1/p62 (sequestosome 1) and CTSD (cathepsin D), and by the abundance of autophagic vacuoles and lysosomes detected electron-microscopically. AMP-activated protein kinase (AMPK) was activated and ATP content was reduced in type 1 diabetic hearts. Treatment with chloroquine, an autophagy inhibitor, worsened cardiac performance in type 1 diabetes. In addition, hearts from db/db type 2 diabetic model mice exhibited poorer diastolic function than control hearts from db/+ mice. However, levels of LC3-II, SQSTM1 and phosphorylated MTOR (mechanistic target of rapamycin) were increased, but CTSD was decreased and very few lysosomes were detected ultrastructurally, despite the abundance of autophagic vacuoles. AMPK activity was suppressed and ATP content was reduced in type 2 diabetic hearts. These findings suggest the autophagic process is suppressed at the final digestion step in type 2 diabetic hearts. Resveratrol, an autophagy enhancer, mitigated diastolic dysfunction, while chloroquine had the opposite effects in type 2 diabetic hearts. Autophagy in the heart is enhanced in type 1 diabetes, but is suppressed in type 2 diabetes. This difference provides important insight into the pathophysiology of diabetic cardiomyopathy, which is essential for the development of new treatment strategies.

          Related collections

          Author and article information

          Journal
          Autophagy
          Autophagy
          1554-8635
          1554-8627
          2015
          : 11
          : 7
          Affiliations
          [1 ] a Department of Cardiology; Gifu University Graduate School of Medicine ; Gifu , Japan.
          Article
          10.1080/15548627.2015.1051295
          4590644
          26042865

          Comments

          Comment on this article